Although this strategy offers a lower risk profile compared to completely innovative drugs and can be enormously successful in some cases (e.g. atorvastatin is an improvement on lovastatin, esomeprazole successfully replaced omeprazole), we believe that times and regulations have increasingly turned ...
Zanubrutinib decreased systemic exposure of midazolam and omeprazole (CYP3A and CYP2C19 substrates, respectively). A clinical trial to assess the use of CYP3A inducers (n = 20) or inhibitors (n = 18) in combination with zanubrutinib in Asian and non-Asian patients verified that zanubrutinib...